Related Experiment Video
Updated: Jan 28, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Treatment Update of Autoimmune Blistering Diseases
Khalaf Kridin1, Christine Ahn2, William C Huang2
1Department of Dermatology, Rambam Health Care Campus, POB 9602, Haifa 31096, Israel.
Abstract:
The treatment of refractory autoimmune blistering diseases (AIBDs) has always been a challenge. Because randomized controlled trials are lacking, treatment has been based on analysis of anecdotal data. The last 2 decades has seen the use of rituximab become a conventional treatment in the therapeutic armamentarium of AIBDs, leading to its Food and Drug Administration indication for pemphigus vulgaris in 2018. We review the current updated data on the use of rituximab including dosing, protocols, and its role in the algorithm of AIBDs. In addition, we discuss several promising novel emerging therapeutic agents for AIBDs.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

